Researchers may have discovered a way to reverse osteoporosis by activating a built-in bone-strengthening switch known as GPR133. Biochemist Ines Liebscher and molecular biologist Juliane Lehmann at Leipzig University in Germany, alongside colleagues at Shandong University in China, found that this receptor acts as a sensor on bone-forming cells called osteoblasts. When adjacent bone cells make contact and the skeleton experiences mechanical strain, GPR133 switches on, accelerating bone formation while suppressing the cells responsible for breaking bone down.
In laboratory tests, mice lacking a functional GPR133 receptor experienced early-onset bone density loss closely resembling human osteoporosis. However, when the research team treated mice with AP503, a compound identified via computer screening to activate GPR133, bone strength improved dramatically in both healthy mice and those with osteoporotic bones.
Because existing osteoporosis medications primarily slow further bone deterioration rather than regenerating lost tissue, a therapy capable of actively rebuilding bone would mark a major advancement, particularly for postmenopausal women. Furthermore, earlier research demonstrated that AP503 also strengthens skeletal muscle, leading scientists to believe it could be paired with physical exercise to stimulate even greater bone growth.
While these findings are currently limited to animal models and AP503 has not yet undergone human clinical trials, the GPR133 receptor is directly linked to human bone density. Consequently, researchers view it as a highly promising therapeutic target for protecting bone health in aging populations.
[Lehmann, J., Lin, H., Zhang, Z., Wiermann, M., Ricken, A. M., Brinkmann, F., Brendler, J., Ullmann, C., Bayer, L., Berndt, S., Penk, A., Winkler, N., Hirsch, F. W., Fuhs, T., Kรคs, J., Xiao, P., Schรถneberg, T., Rauner, M., Sun, J.-P., & Liebscher, I. (2025). The mechanosensitive adhesion G protein-coupled receptor 133 (GPR133/ADGRD1) enhances bone formation. *Signal Transduction and Targeted Therapy*, 10(1), 199]
A single dose of a gene-editing treatment cut bad cholesterol by 62%, and the effect has lasted up to 18 months so far.
The treatment, VERVE-102, made by Verve Therapeutics, now part of Eli Lilly, uses a precise form of gene editing called base editing to turn off PCSK9, a liver gene that makes a protein that stops the body from clearing LDL, the "bad" cholesterol.
It's given in a single IV infusion, with the editing instructions packed into tiny fat bubbles that carry them to the liver.
In the Heart-2 trial, 35 adults with inherited high cholesterol or early heart disease, whose levels stayed too high despite their usual medication, each received one of six doses.
At the highest dose, PCSK9 fell by 88% and LDL cholesterol by an average of 62%. There were no treatment-related serious side effects, and in the people followed longest, the drop has held for up to 18 months.
High LDL is one of the main drivers of heart attacks and strokes, and keeping it down usually means taking pills every day for life. Around half of patients stop their cholesterol medication within a year, often because daily pills are hard to keep up with or cause side effects, so a one-time treatment could protect people who fall through those gaps. "It is still early days, but this is an extremely exciting milestone," said UCL cardiologist Riyaz Patel.
Still, this was a small, early trial funded by the company, and lower doses produced much smaller drops, as little as 9%. And because the edit is permanent, participants will be followed for up to 15 years to check for long-term safety problems. Lilly plans to launch a larger phase 2 trial by the end of 2026.
source: Vafai, S. B., et al. (2026). In vivo base editing of PCSK9 with VERVE-102 for hypercholesterolemia. New England Journal of Medicine. BBC Science Focus. (2026). Landmark treatment slashes cholesterol by 62% with a single dose.
Reversing aging might one day be as simple as a pill, if this Harvard research holds up.
A team led by David Sinclair at Harvard Medical School, with colleagues at MIT and the University of Maine, screened combinations of small molecules to see if any could turn back the clock inside aging cells.
They built tests that tell young cells from old ones, including an โaging clockโ that reads which genes are switched on and a live test of how well a cell keeps its proteins in the right compartments.
They found six chemical cocktails that restored youthful patterns in both, reversing the cells' measured age in less than a week.
The same lab had previously rejuvenated cells using three โYamanakaโ genes delivered by a virus, an approach that has restored vision in old mice and is being prepared for human trials.
Chemicals are far easier to give than gene therapy, which is why the team hopes this could one day lead to a pill for age-related diseases. This was a 2023 study in cells in the lab, and the cocktails have not been tested in people.
source: Yang, J.-H., Petty, C. A., Dixon-McDougall, T., et al., & Sinclair, D. A. (2023). Chemically induced reprogramming to reverse cellular aging. Aging, 15(13).
Two photons being entangled in real-time assumed the shape of yin and yang.
Physicists from the University of Ottawa and Sapienza University of Rome published a breakthrough study in Nature Photonics introducing a method called biphoton digital holography. To prove that their new quantum camera could accurately reconstruct data, they projected a laser beam structured in the shape of a yin-yang symbol into the apparatus.
The successful real-time reconstruction resulted in this impressive image, but the scientists could have chosen a smiley face or a letter of the alphabet to achieve the exact same result.
The true scientific revolution lies in the transition from traditional quantum tomography to digital holography. Previously, measuring the complete quantum state of entangled particles required taking thousands of individual measurements from different angles, a tedious process that could take hours or even days. The new holographic method works by overlapping the unknown photon state with a known reference state and capturing the resulting 2D interference pattern. This allows researchers to extract the full wave function of the entangled photons in just seconds or minutes.
๐จ Scientists in France developed an artificial heart that can adapt to the body's needs.
What if a machine could do more than pump blood?
The French-developed Aeson artificial heart uses sensors and intelligent control systems to adjust blood flow according to the body's changing demands.
Unlike many conventional mechanical devices, it uses specially processed animal tissue in parts that contact the blood, alongside advanced pumping technology designed to mimic the natural heart's movements.
The goal is to help people with severe heart failure whose hearts can no longer pump enough blood. For carefully selected patients, the device can serve as a bridge to a heart transplant.
But there is a catch. The system still depends on external batteries and equipment, and its long-term reliability remains an important consideration.
Could artificial hearts one day help more people survive when donor hearts are unavailable? Scientists are working toward that future, but significant challenges remain.
Source: European Commission. (n.d.). The world's only bioprosthetic auto-regulated artificial heart. CORDIS. European Commission research project
๐จ THE PASTA SECRET YOUR BLOOD SUGAR DOESNโT WANT YOU TO KNOWโฆ
You cook your pasta, eat it, and feel that quick spike in energyโฆ and then the crash. But what if I told you that leaving your pasta in the fridge for just 24 hours could secretly transform it into something that feeds your gut and slows sugar spikes? Scientists have found that cooled pasta changes some of its starch into โresistant starchโ, a type your body canโt fully digest.
This means less blood sugar surge and a hidden boost for your gut bacteria. Even more surprising? Reheating it doesnโt destroy all of this magical starch. The next time you make spaghetti, you might just want to cook, chill, and then enjoy. Who knew your leftover pasta could be a secret health weapon?
Source: Nugent, A. (Resistant starch and health effects)
A former NASA engineer says his team has identified an electrostatic "New Force" that can generate thrust without any propellant, potentially challenging established physics and enabling devices capable of countering Earth's gravity.
Dr. Charles Buhler, a longtime NASA veteran and co-founder of Exodus Propulsion Technologies, claims that his group has uncovered a novel force produced purely through electric fields. Their experimental propulsion system creates directional thrust without expelling mass, unlike conventional rockets that rely on large amounts of heavy fuel. If validated, this propellantless technology could revolutionize spaceflight by slashing spacecraft weight and making sustained, fuel-free exploration of deep space possible.
The broader scientific community remains cautious. A reactionless drive of this kind would appear to contradict Newton's third law and the conservation of momentum. Earlier claims for "impossible" engines, such as the EmDrive, were ultimately debunked after careful testing eliminated experimental artifacts.
Buhler's extensive expertise in electrostatics, developed at NASA's Kennedy Space Center, gives the announcement more credibility than most fringe proposals. Nevertheless, the results require rigorous independent replication and peer-reviewed validation before they can be accepted as a genuine breakthrough.
๐จ: New research indicates that we are not the only conscious beings on this planetโฆ
Groundbreaking botanical research challenges human exceptionalism, suggesting that the trillions of trees and plants surrounding us possess spatial awareness, intentionality, and a form of consciousness.
Historically, humans have viewed plants as passive background scenery, but a series of compelling scientific studies is flipping this anthropocentric script. According to plant neurobiologist Dr. Stefano Mancuso, plants exhibit behaviors that closely mirror conscious animal action. In laboratory experiments, scientists observed that plants respond to anesthesia in the exact same manner as humans, with species like the Venus Flytrap becoming completely nonresponsive. Furthermore, time-lapse research shows bean plants demonstrating remarkable spatial awareness and intentionality, aiming their shoots to hook onto physical supports and even altering their growth strategy if they detect a competitor has reached a support first.
These findings suggest that consciousness is not a biological trait exclusive to organisms with brains, but rather a flexible phenomenon that can thrive in very different life forms. As trees globally migrate northward to escape warming climatesโresembling animal migration patternsโresearchers argue that our concept of 'mind' must expand. With over three trillion trees on Earth, recognizing plant consciousness could fundamentally reshape our ethical systems, agricultural practices, and relationship with the natural world. Instead of treating the environment as inert raw material, we may have to start viewing plant communities as active, aware partners in a shared ecosystem.
source: Lahey, S. (2026). We May Be Surrounded by Trillions of Conscious Beings, Research SuggestsโAnd They Aren't Human. Popular Mechanics.
๐ฉบ๐ค ๐ช๐ต๐ ๐๐ #๐๐ ๏ฟฝ๏ฟฝ๐ฒ๐ฐ๐ผ๐บ๐ถ๐ป๐ด ๐๐ต๐ฒ ๐ ๐ผ๐๐ ๐ฃ๐ผ๐๐ฒ๐ฟ๐ณ๐๐น ๐๐ผ๐ฟ๐ฐ๐ฒ ๐ถ๐ป ๐ ๐ผ๐ฑ๐ฒ๐ฟ๐ป #๐๐ฒ๐ฎ๐น๐๐ต๐ฐ๐ฎ๐ฟ๐ฒโ
๐ฉบ๐ค ูู ููู #ุงูุฐูุงุก_ุงูุงุตุทูุงุนู ูุฑุงุก ุฃูุจุฑ ุชุญูู ูู ุชุงุฑูุฎ ุงูุฑุนุงูุฉ ุงูุตุญูุฉุ
๐ฏ Healthcare is about to experience its biggest transformation in history.
AI is no longer just supporting healthcare โ Itโs becoming an essential partner in prediction, diagnosis, treatment & clinical decision-making.
Here are 7๏ธโฃ ๐ธ๐ฒ๐ ๐๐ฎ๐๐ AI is transforming modern healthcare ๐
1๏ธโฃ ๐ฃ๐ฟ๐ฒ๐ฑ๐ถ๐ฐ๐๐ถ๐๐ฒ ๐๐ฒ๐ฎ๐น๐๐ต๐ฐ๐ฎ๐ฟ๐ฒ
โ Healthcare is shifting from reactive to preventive.
โ Early disease prediction
โ Risk stratification
โ Preventive interventions
2๏ธโฃ ๐๐ฎ๐ฟ๐น๐ถ๐ฒ๐ฟ ๐๐ถ๐ฎ๐ด๐ป๐ผ๐๐ถ๐
โ AI detects patterns invisible to the human eye.
โ Earlier intervention
โ Higher diagnostic accuracy
โ Reduced diagnostic errors
3๏ธโฃ ๐ฃ๐ฒ๐ฟ๐๐ผ๐ป๐ฎ๐น๐ถ๐๐ฒ๐ฑ ๐ ๐ฒ๐ฑ๐ถ๐ฐ๐ถ๐ป๐ฒ
โ Every patient is unique & treatment should be too.
โ Precision therapies
โ Genomic medicine
โ Better patient outcomes
4๏ธโฃ ๐๐ ๐๐น๐ถ๐ป๐ถ๐ฐ๐ฎ๐น ๐๐๐๐ถ๐๐๐ฎ๐ป๐๐
โ AI is becoming every clinicianโs intelligent co-pilot.
โ Faster clinical decisions
โ Less administrative work
โ More time for patients
5๏ธโฃ ๐ช๐ฒ๐ฎ๐ฟ๐ฎ๐ฏ๐น๐ฒ๐ & ๐๐ผ๐ป๐๐ถ๐ป๐๐ผ๐๐ ๐ ๐ผ๐ป๐ถ๐๐ผ๐ฟ๐ถ๐ป๐ด
โ Healthcare is moving beyond hospitals into everyday life.
โ Real-time monitoring
โ Remote patient care
โ Personalized health insights
6๏ธโฃ ๐๐ป๐๐ฒ๐น๐น๐ถ๐ด๐ฒ๐ป๐ ๐๐ผ๐๐ฝ๐ถ๐๐ฎ๐น๐
โ AI is transforming how healthcare systems operate.
โ Workflow automation
โ Resource optimization
โ Lower operational costs
7๏ธโฃ ๐๐๐บ๐ฎ๐ป + ๐๐ ๐ฃ๐ฎ๐ฟ๐๐ป๐ฒ๐ฟ๐๐ต๐ถ๐ฝ
โ The future isnโt AI versus clinicians. Itโs clinicians empowered by AI.
โ Better decisions
โ Better care
โ Better patient outcomes
๐ฌ Which healthcare application of AI do you believe will have the greatest impact over the next decadeโ
#HealthTech #DigitalHealth #ArtificialIntelligence #Innovation
@enilev@Jagersbergknut@TysonLester@CurieuxExplorer@GlenGilmore@FrRonconii@chidambara09@jeancayeux@mvollmer1@Nicochan33@RLDI_Lamy@pchamard@mikeflache@Fabriziobustama@ThEiLe0@Mack1510019@ipfconline1@PawlowskiMario@drsharwood@kalydeoo@baski_LA@AnthonyRochand@smaksked@Eli_Krumova@andresvilarino@gvalan@AI_4_Healthcare@bimedotcom@arlenenewbigg@NewsNeus@domingonarvaez1@bamitav@jornalistavitor@jblefevre60@thomas_dettling@FmFrancoise@nafisalam@Mhcommunicate@Corix_JC@c4trends@smoothsale@amalmerzouk@PVynckier@bbailey39@NathaliaLeHen@jasuja@ralf_ladner@mary_gambara
๐ง๐ต๐ฒ ๐๐น๐ผ๐ฏ๐ฎ๐น ๐ฅ๐ฎ๐ฐ๐ฒ ๐๐ผ ๐๐๐ถ๐น๐ฑ #AI-๐ฃ๐ผ๐๐ฒ๐ฟ๐ฒ๐ฑ #๐๐๐บ๐ฎ๐ป๐ผ๐ถ๐ฑ #๐ฅ๐ผ๐ฏ๐ผ๐๏ฟฝ#๐ฅ๐ผ๐ฏ๐ผ๐๐ ๐๐ฎ๐ ๏ฟฝ๏ฟฝ๐ฒ๐ด๐๐ป๐ค
ุจุฏุฃ ุงูุณุจุงู ุงูุนุง๏ฟฝ๏ฟฝู ู ูุจูุงุก #ุงูุฑูุจูุชุงุช ุงูุจุดุฑูุฉ ุงูู ุฏุนูู ุฉ ุจู #ุงูุฐูุงุก_ุงูุงุตุทูุงุนู
The next major #AI platform may not live inside a screenโคต๏ธ
It may ๐๐ฎ๐น๐ธ, ๐น๐ฒ๐ฎ๐ฟ๐ป, ๐๐ผ๐ฟ๐ธ & ๐ผ๐ฝ๐ฒ๐ฟ๐ฎ๐๐ฒ alongside us.
Save this ๐
Here are 12 companies shaping the humanoid robotics race โคต๏ธ
๐บ๐ธ 1๏ธโฃ ๐๐ถ๐ด๐๐ฟ๐ฒ
Building general-purpose humanoid robots for commercial environments.
๐บ๐ธ 2๏ธโฃ ๐ง๐ฒ๐๐น๐ฎ
Developing Optimus around AI, manufacturing scale and real-world tasks.
๐ฉ๐ช 3๏ธโฃ ๐ก๐๐จ๐ฅ๐ ๐ฅ๐ผ๐ฏ๐ผ๐๐ถ๐ฐ๐
Combining cognitive robotics with human-centered industrial applications.
๐จ๐ณ 4๏ธโฃ ๐จ๐ป๐ถ๐๐ฟ๐ฒ๐ฒ
Advancing increasingly capable and accessible humanoid platforms.
๐จ๐ณ 5๏ธโฃ ๐๐ด๐ถ๐๐ผ๐
Developing humanoid robots for industrial and commercial deployment.
๐จ๐ณ 6๏ธโฃ ๐จ๐๐ง๐๐๐
Moving humanoid robots toward factory and enterprise environments.
๐บ๐ธ 7๏ธโฃ ๐๐ฝ๐ฝ๐๐ฟ๐ผ๐ป๐ถ๐ธ
Building Apollo for logistics, manufacturing and physically demanding work.
๐จ๐ณ 8๏ธโฃ ๐๐ฎ๐น๐ฏ๐ผ๐
Developing embodied AI for service and industrial applications.
๐บ๐ธ 9๏ธโฃ ๐๐ด๐ถ๐น๐ถ๐๐ ๐ฅ๐ผ๐ฏ๐ผ๐๐ถ๐ฐ๐
Deploying Digit for logistics and repetitive workplace tasks.
๐ณ๐ด 10- ๐ญ๐ซ
Focusing on humanoid robots designed to operate in everyday environments.
๐บ๐ธ 11- ๐ฆ๐๐ป๐ฑ๐ฎ๐ ๐ฅ๐ผ๐ฏ๐ผ๐๐ถ๐ฐ๐
Building general-purpose robots for practical human environments.
๐บ๐ธ 12- ๐๐ผ๏ฟฝ๏ฟฝ๐๐ผ๐ป ๐๐๐ป๐ฎ๐บ๐ถ๐ฐ๐
Pushing the boundaries of mobility, balance and advanced robotics.
โก ๐๐๐ ๐๐ต๐ฒ ๐ฏ๐ถ๐ด๐ด๐ฒ๐ฟ ๐๐ต๐ถ๐ณ๐ ๐ถ๐ ๐๐ต๐ถ๐:
AI is moving from ๐ฑ๐ถ๐ด๐ถ๐๐ฎ๐น ๐ถ๐ป๐๐ฒ๐น๐น๐ถ๐ด๐ฒ๐ป๐ฐ๐ฒ to ๐ฒ๐บ๐ฏ๐ผ๐ฑ๐ถ๐ฒ๐ฑ ๐ถ๐ป๐๐ฒ๐น๐น๐ถ๐ด๐ฒ๐ป๐ฐ๐ฒ.
From systems that ๐ฎ๐ป๐๐๐ฒ๐ฟ
to machines that ๐๐ฒ๐ฒ, ๐บ๐ผ๐๐ฒ, ๐น๐ฒ๐ฎ๐ฟ๐ป & ๐ฎ๐ฐ๐.
๐ก ๐ ๐ ๐ง๐ฎ๐ธ๐ฒ:
The humanoid robotics race will not be won by whoever creates the most human-looking machine.
It will be won by whoever solves ๐ถ๐ป๐๐ฒ๐น๐น๐ถ๐ด๐ฒ๐ป๐ฐ๐ฒ, ๐ฑ๐ฒ๐ ๐๐ฒ๐ฟ๐ถ๐๐, ๐๐ฎ๐ณ๐ฒ๐๐, ๐ฟ๐ฒ๐น๐ถ๐ฎ๐ฏ๐ถ๐น๐ถ๐๐ & ๐๐ฐ๐ฎ๐น๐ฒ.
๐๐ฒ๐ป๐ฒ๐ฟ๐ฎ๐๐ถ๐๐ฒ AI โก๏ธ ๐๐ด๐ฒ๐ป๐๐ถ๐ฐ AI โก๏ธ ๐ฃ๐ต๐๐๐ถ๐ฐ๐ฎ๐น AI
The real question is no longer whether humanoid robots are coming.
๐๐ ๐ถ๐ ๐๐ต๐ฒ๐ฟ๐ฒ ๐๐ต๐ฒ๐ ๐๐ถ๐น๐น ๐ฒ๐ป๐๐ฒ๐ฟ ๐ผ๐๐ฟ ๐น๐ถ๐๐ฒ๐ ๐ณ๐ถ๐ฟ๐๐๐ค
Which company do you believe will lead the humanoid robotics race?
#HumanoidRobots #Robotics #PhysicalAI #FutureTech
@enilev @Jagersbergknut @TysonLester @CurieuxExplorer @GlenGilmore @FrRonconii @chidambara09 @jeancayeux @mvollmer1 @Nicochan33 @RLDI_Lamy @pchamard @mikeflache @Fabriziobustama @ThEiLe0 @Mack1510019 @ipfconline1 @PawlowskiMario @drsharwood @kalydeoo @baski_LA @AnthonyRochand @smaksked @Eli_Krumova @andresvilarino @gvalan @AI_4_Healthcare @bimedotcom @arlenenewbigg @NewsNeus @domingonarvaez1 @bamitav @jornalistavitor @jblefevre60 @thomas_dettling @FmFrancoise @nafisalam @Mhcommunicate @Corix_JC @c4trends @smoothsale @amalmerzouk @PVynckier @bbailey39 @NathaliaLeHen @jasuja @ralf_ladner @mary_gambara
Forcing employees to begin their day before 10 a.m. creates chronic sleep deprivation and is counter to human biology.
Traditional 9-to-5 schedules are fundamentally out of sync with human biology, leaving millions of workers and students in a state of perpetual exhaustion.
Oxford University sleep scholar Dr. Paul Kelley warns that forcing individuals aged 10 to 55 to start work or school before 10 a.m. puts severe biological stress on internal organs like the heart and liver.
Because the body's internal circadian rhythm is regulated by light exposure controlled through the brain's hypothalamus, people cannot simply train themselves to wake up earlier without damaging their physical, emotional, and cognitive systems.
Scientists 3D-printed a heart using human cells โ and the results could change medicine forever!
Imagine a future where damaged hearts could one day be replaced with organs grown from a patient's own cells. Scientists at Tel Aviv University in Israel took an important step toward that possibility in 2019.
Using human cells and biological materials from fatty tissue, researchers created a miniature, 3D-printed heart complete with chambers and blood vessels. The technology even allowed them to use materials derived from the same patient, potentially helping reduce the risk of immune rejection.
But there's a catch. The tiny heart was not yet capable of pumping blood like a healthy human heart. Scientists still needed to overcome major challenges before such technology could produce fully functional replacement organs.
The ultimate goal? To develop personalized hearts that could one day help address the shortage of donor organs.
Could doctors eventually print a replacement heart for someone who needs one? The breakthrough offers a fascinating glimpse into what future medicine might make possible.
Source:
Cohen, J. (2019, April 15). Scientists create world's first 3D-printed heart using human cells. NBC News.
Scientists May Have Found a Way to Wake Up Sleeping Hair Follicles โ And Regrow Lost Hair!
Scientists are testing an experimental treatment called PP405 that could offer a new approach to hair loss. Unlike traditional treatments that mainly focus on slowing hair loss or supporting existing hair growth, PP405 targets the energy-producing processes inside dormant hair follicle stem cells, aiming to switch them back into an active growth state.
In a Phase 2a clinical trial involving 78 men and women with pattern hair loss, participants applied PP405 or a placebo to their scalps daily for four weeks. The results offered an encouraging sign: among men with more advanced hair loss, 31% of those who received PP405 experienced an increase in hair density of more than 20% by week eight. That was four weeks after they had stopped using the treatment. No participants in the placebo group achieved the same level of improvement.
But thereโs another reason researchers are interested in this treatment. The findings suggest that hair growth may be possible in areas where hair was no longer visibly present. This raises an exciting possibility: some areas of a thinning scalp may still contain hair follicles with the potential to become active again.
The early safety results were also encouraging. PP405 was well tolerated during the study, and researchers detected no measurable amount of the drug entering participantsโ bloodstreams. However, the trial was small, and the results do not yet prove that the treatment will work for everyone or produce lasting results.
Developed by Pelage Pharmaceuticals, PP405 is still experimental. Larger clinical trials are needed to establish how effective it is, how long the results last, and which people are most likely to benefit.
Could waking up dormant hair follicles become the next major breakthrough in treating baldness? Researchers are now working to find out.
Source: Pelage Pharmaceuticals, Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy (2025).
Scientists May Have Found a Way to Wake Up Sleeping Hair Follicles โ And Regrow Lost Hair!
Scientists are testing an experimental treatment called PP405 that could offer a new approach to hair loss. Unlike traditional treatments that mainly focus on slowing hair loss or supporting existing hair growth, PP405 targets the energy-producing processes inside dormant hair follicle stem cells, aiming to switch them back into an active growth state.
In a Phase 2a clinical trial involving 78 men and women with pattern hair loss, participants applied PP405 or a placebo to their scalps daily for four weeks. The results offered an encouraging sign: among men with more advanced hair loss, 31% of those who received PP405 experienced an increase in hair density of more than 20% by week eight. That was four weeks after they had stopped using the treatment. No participants in the placebo group achieved the same level of improvement.
But thereโs another reason researchers are interested in this treatment. The findings suggest that hair growth may be possible in areas where hair was no longer visibly present. This raises an exciting possibility: some areas of a thinning scalp may still contain hair follicles with the potential to become active again.
The early safety results were also encouraging. PP405 was well tolerated during the study, and researchers detected no measurable amount of the drug entering participantsโ bloodstreams. However, the trial was small, and the results do not yet prove that the treatment will work for everyone or produce lasting results.
Developed by Pelage Pharmaceuticals, PP405 is still experimental. Larger clinical trials are needed to establish how effective it is, how long the results last, and which people are most likely to benefit.
Could waking up dormant hair follicles become the next major breakthrough in treating baldness? Researchers are now working to find out.
Source: Pelage Pharmaceuticals, Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy (2025).
๐ง ๐๐ซ๐๐ข๐ง-๐๐จ๐ฆ๐ฉ๐ฎ๐ญ๐๐ซ ๐๐ง๐ญ๐๐ซ๐๐๐๐ Is ๐๐จ ๐๐จ๐ง๐ ๐๐ซ ๐๐๐ข๐๐ง๐๐ ๐ ๐ข๐๐ญ๐ข๐จn TY @Khulood_Almani
By 2030 -1๏ธโฃthought-to-text communication โก๏ธ direct human-AI interaction symbiosis #AI#BrainComputerInterface#FutureTech#AGI#HumanAI@dinisguarda@Shi4Tech
#AgenticAI/ Interesante Infografia apreciada Khulood. Una economรญa de IA mรกs autรณnoma requiere una infraestructura de confianza igualmente sofisticada !Gracias por compartir.
Sun Zhiwei, a 61-year-old number theory professor at Nanjing University, has compiled over 1,000 original unsolved mathematical conjectures in a 400-page collection, some paired with cash prizes funded from his own salary. Sun argues that AI is a capable mathematical assistant but cannot replace the human ability to ask genuinely new questions. He describes AI as โa highly knowledgeable, diligent and intelligent graduate studentโ that needs human guidance, and even cuts off its internet access when assigning hard problems so it cannot discover they remain unsolved and refuse to work on them. Some of his most difficult problems he calls โalien conjectures,โ problems he believes current human mathematics cannot solve. Sunโs approach to mathematics shifted after a 2005 visiting professorship, when he learned to use computational software to validate thousands of cases at once, triggering what he describes as a sudden creative breakthrough.
A NEW HOPE FOR LYMPHEDEMA PATIENTS: AN EXPERIMENTAL PILL REDUCED LEG SWELLING BY OVER 1 LITER!
For millions of people living with lymphedema, even simple daily activities can become difficult because of persistent swelling, pain, and hardened skin. Now, an experimental oral drug called acebilustat could offer a new way to manage this challenging condition.
In a clinical study published in Scientific Reports, researchers led by Stanford University School of Medicine investigated whether the drug could help people with lymphedema, a condition in which lymph fluid builds up in body tissues because the lymphatic system cannot drain it properly. After 12 months of daily treatment, participants experienced an average reduction of 1,012 milliliters in leg volumeโmore than one liter. Researchers also reported improvements in skin thickness and tissue scarring, raising hopes for people who struggle with long-term swelling.
Lymphedema can develop after cancer treatment, surgery, radiation, or damage to the lymphatic system. It can cause discomfort, limit movement, harden the skin, and increase the risk of serious skin infections. Current management often involves compression garments, specialized massage, exercise, and other forms of physical therapy that patients may need to follow for years.
Acebilustat works by targeting leukotriene B4, an inflammatory substance linked to damage in lymphatic tissues. By blocking this pathway, the drug aims to reduce inflammation and help limit the changes that make lymphedema so difficult to manage.
The findings offer encouraging hope, but there is an important limitation: acebilustat remains experimental for lymphedema. More research is needed to confirm its effectiveness and safety before it can be considered a standard treatment. It is not yet a proven replacement for existing therapies.
If further studies confirm these results, a daily pill could eventually become an important addition to treatment for people living with this chronic condition.
Source: Rockson, S. G., et al. (2026). Therapeutic selective leukotriene B4 antagonism for human lymphedema. Scientific Reports.